Article

Effect of an interieukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

University of Pittsburgh, Division of Pulmonary, Allergy, and Critical Care Medicine, Pittsburgh, PA, USA.
The Lancet (Impact Factor: 39.21). 11/2007; 370(9596):1422-31. DOI: 10.1016/S0140-6736(07)61600-6
Source: PubMed

ABSTRACT Increases in T helper (Th) 2 cytokine concentrations have been seen in atopic asthma, with interleukin 4 and interleukin 13 thought to have a role in the physiological response to allergen challenge. Our aim was to assess the therapeutic effect of pitrakinra, an interleukin-4 variant that targets allergic Th2 inflammation by potently inhibiting the binding of interleukin 4 and interleukin 13 to interleukin-4Ralpha receptor complexes.
In two independent randomised, double-blind, placebo-controlled, parallel group phase 2a clinical trials, patients with atopic asthma were treated with pitrakinra or placebo via two routes. In study 1, patients were randomly assigned to receive either 25 mg pitrakinra (n=12) or placebo (n=12) by subcutaneous injection once daily. In study 2, patients were randomly assigned to receive either 60 mg pitrakinra (n=16) or placebo (n=16) by nebulisation twice daily. Inhaled allergen challenge was done before and after 4 weeks of treatment. The primary endpoint for study 1 was maximum percentage decrease in forced expiratory volume in 1 s (FEV1) over 4-10 h after allergen challenge, whereas that in study 2 was average percentage decrease in FEV(1) over 4-10 h after allergen challenge. All patients except those with baseline data only were included in our analyses. These trials are registered with ClinicalTrials.gov, numbers NCT00535028 and NCT00535031.
No patients dropped out or were lost to follow-up in study 1; in study 2, two patients in the placebo group and one in the pitrakinra group dropped out or were lost to follow-up. These individuals had baseline data only, and were excluded from the analyses. In study 1, there was a 17.1% maximum percentage decrease in FEV1 in the pitrakinra group; by contrast, the maximum decrease was 23.1% in the placebo group (difference 6%, 95% CI -4.37 to 16.32; p=0.243). In study 2, there was a 4.4% average percentage decrease in FEV1 in the pitrakinra group; by contrast, the average percentage decrease was 15.9% in the placebo group (3.7 [95% CI 2.08-6.25] times lower in the pitrakinra group; p=0.0001). There were fewer asthma-related adverse events (p=0.069) and fewer adverse events requiring beta-agonist rescue (p=0.031) after subcutaneous administration of pitrakinra than with placebo. There were too few asthma-related adverse events in study 2 to assess the effect of inhalation of pitrakinra on adverse events.
Local treatment, targeted at inhibition of interleukins 4 and 13 in the lung, could substantially diminish the symptoms of asthma.

Full-text

Available from: Malinda Longphre, Jun 13, 2015
0 Followers
 · 
206 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The discovery of new pathobiological pathways involved in asthma chronicity and reliefs offers novel therapeutic avenues. Enhanced phenotyping criteria associated with simple biologic characterization allowed to test targeted interventions in selected patients. Long-term studies are de facto lacking but required to address their impact on the natural history of the disease. Here, the authors review all potential available therapeutics based on immunologic pathways involved in asthma pathophysiology during the last decade.
    Clinics in chest medicine 09/2012; 33(3):585-97. DOI:10.1016/j.ccm.2012.06.004 · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Current therapy for asthma with inhaled corticosteroids and long-acting inhaled β2-agonists is highly effective, safe, and relatively inexpensive, but many patients remain poorly controlled. Most advances have been through improving these drug classes and a major developmental hurdle is to improve existing drug classes. Major unmet needs include better treatment of severe asthma (which has some similarity to chronic obstructive pulmonary disease), as well as curative therapies for mild to moderate asthma that do not result in the return of symptoms when the treatment is stopped. Several new treatments are in development, but many are specific, targeting a single mediator or receptor, and are unlikely to have a major clinical impact, although they may be effective in specific asthma phenotypes (endotypes). Drugs with more widespread effects, such as kinase inhibitors, may be more effective but have a greater risk of side effects so inhaled delivery may be needed. Several new treatments target the underlying allergic/immune process and would treat concomitant allergic diseases. Improved immunotherapy approaches have the potential for disease modification, although prospects for a cure are currently remote.
    Seminars in Respiratory and Critical Care Medicine 12/2012; 33(6):685-94. DOI:10.1055/s-0032-1326965 · 3.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although asthma is recognized as a heterogeneous disease associated with clinical phenotypes, the molecular basis of these phenotypes remains poorly understood. While genomic studies have successfully broadened our understanding in diseases such as cancer, they have not been widely used in asthma studies. To link gene expression patterns to clinical asthma phenotypes, we utilized a microarray platform to analyze bronchial airway epithelial cell (BAEC) gene expression in relation to the asthma biomarker fractional exhaled nitric oxide (FeNO) in 155 asthmatic subjects and healthy controls from the Severe Asthma Research Program (SARP). We first identified a diverse set of 549 genes whose expression correlated with FeNO. We used K-means to cluster the patient samples according to the expression of these genes, identifying 5 asthma clusters/phenotypes with distinct clinical, physiological, cellular and gene transcription characteristics-termed 'subject clusters' (SCs). To then investigate differences in gene expression between SCs, a total of 1384 genes were identified which highly differentiated the SCs at an unadjusted p-value of <10-6. Hierarchical clustering of these 1384 genes identified 9 gene clusters (GCs) or 'biclusters', whose coexpression suggested biological characteristics unique to each SC. While genes related to Type-2 inflammation were present, novel pathways, including those related to neuronal function, WNT pathways and actin cytoskeleton, were also noted. These findings show that bronchial epithelial cell gene expression, as related to the asthma biomarker FeNO, can identify distinct asthma phenotypes, while also suggesting the presence of underlying novel gene pathways relevant to these phenotypes.
    American Journal of Respiratory and Critical Care Medicine 10/2014; DOI:10.1164/rccm.201406-1099OC · 11.99 Impact Factor